^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ABL1 (ABL proto-oncogene 1)

    i
    Apply
    Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (A041703) (NCT03739814)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/08/2019
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    ABL1 • BCR • CD22
    |
    CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (NCT00792948)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2016
    Completion :
    01/06/2026
    ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (NCI-2017-02296) (NCT03375307)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/03/2020
    Primary completion :
    12/16/2025
    Completion :
    12/16/2025
    TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC
    |
    FANCG mutation
    |
    Lynparza (olaparib)
    Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (AALL1131) (NCT02883049)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/29/2012
    Primary completion :
    12/31/2022
    Completion :
    10/03/2025
    ABL1 • BCR • RUNX1 • KMT2A • ETV6
    |
    MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (NCT04530565)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    01/25/2021
    Primary completion :
    07/01/2028
    Completion :
    07/01/2028
    ABL1 • BCR
    |
    ABL1 T315I
    |
    dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
    Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors (NCT03610971)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/19/2019
    Primary completion :
    02/01/2025
    Completion :
    02/01/2026
    ABL1 • BCR
    |
    Jakafi (ruxolitinib)
    Venetoclax Basket Trial for High Risk Hematologic Malignancies (NCT05292664)
    Phase 1
    Andrew E. Place, MD
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    03/29/2023
    Primary completion :
    07/02/2026
    Completion :
    07/02/2028
    FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1
    |
    KMT2A rearrangement • ABL1 fusion
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane
    Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (NCT00390793)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    09/28/2006
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    ABL1 • BCR
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)
    A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (NCT06124157)
    Phase 3
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/14/2025
    Initiation :
    05/29/2025
    Primary completion :
    12/01/2030
    Completion :
    12/01/2030
    ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R
    |
    CD19 expression
    |
    dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
    Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (ASC4MORE) (NCT03578367)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    11/22/2018
    Primary completion :
    11/08/2021
    Completion :
    02/27/2025
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib) • Scemblix (asciminib)
    Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (INCB 84344-102) (NCT03934372)
    Phase 1/2
    Incyte Biosciences International Sàrl
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    01/29/2020
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    FLT3 • ABL1 • BCR • RET • FGFR • BLM
    |
    EGFR mutation • KIT mutation • FGFR mutation • RET mutation
    |
    Iclusig (ponatinib)
    Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors (NCT04795427)
    Phase 2
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    12/06/2021
    Primary completion :
    05/29/2023
    Completion :
    11/18/2024
    ABL1 • BCR
    |
    Scemblix (asciminib)
    Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (MCC-20963) (NCT05177211)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/01/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    ABL1 • BCR
    |
    Inrebic (fedratinib)
    Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (AALL1631) (NCT03007147)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/08/2017
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R
    |
    BCR-ABL1 fusion • ABL1 fusion
    |
    imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone
    Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (NCT05457556)
    Phase 3
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/15/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C
    |
    FLT3-ITD mutation
    |
    Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)
    Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (NCT03817398)
    Phase 2
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    11/08/2019
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    ABL1 • BCR
    Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (NCI-2018-01186) (NCT03147612)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/08/2018
    Primary completion :
    02/28/2027
    Completion :
    02/28/2027
    ABL1 • BCR
    |
    Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (Ascembl) (NCT03106779)
    Phase 3
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    10/26/2017
    Primary completion :
    05/25/2020
    Completion :
    12/04/2024
    ABL1 • BCR
    |
    BCR-ABL1 mutation
    |
    Bosulif (bosutinib) • Scemblix (asciminib)
    A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START) (NCT05456191)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/21/2022
    Primary completion :
    03/17/2025
    Completion :
    07/07/2031
    ABL1
    |
    Tasigna (nilotinib) • Scemblix (asciminib)
    Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease (NCI-2018-00936) (NCT03441061)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/15/2018
    Primary completion :
    02/28/2027
    Completion :
    02/28/2027
    ABL1 • BCR
    |
    Besponsa (inotuzumab ozogamicin)
    Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (SWOG-S1318) (NCT02143414)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    06/30/2015
    Primary completion :
    06/01/2022
    Completion :
    10/23/2025
    ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)
    Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (ECOG-ACRIN E1910) (NCT02003222)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    05/19/2014
    Primary completion :
    06/23/2023
    Completion :
    03/14/2025
    ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTFreedom) (NCT01784068)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/04/2013
    Primary completion :
    05/31/2016
    Completion :
    01/24/2025
    ABL1 • BCR
    |
    BCR-ABL1 E255K • BCR-ABL1 Y253H
    |
    Tasigna (nilotinib)
    Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (NCT01698905)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/20/2012
    Primary completion :
    11/26/2015
    Completion :
    01/19/2025
    ABL1 • BCR
    |
    Tasigna (nilotinib)
    Adding Asciminib to Usual Treatment for Adults with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (NCT06773936)
    Phase 2
    SWOG Cancer Research Network
    Not yet recruiting
    Last update posted :
    01/14/2025
    Initiation :
    03/31/2025
    Primary completion :
    03/01/2029
    Completion :
    05/01/2033
    ABL1 • BCR
    |
    dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)
    RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL) (NCT06684964)
    Phase N/A
    Novartis Pharmaceuticals
    Not yet recruiting
    Last update posted :
    01/10/2025
    Initiation :
    01/30/2025
    Primary completion :
    07/30/2026
    Completion :
    07/30/2026
    ABL1 • BCR
    |
    Scemblix (asciminib)
    Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL (NCT06754267)
    Phase 2
    First Affiliated Hospital of Zhejiang University
    Recruiting
    Last update posted :
    12/31/2024
    Initiation :
    12/01/2024
    Primary completion :
    12/30/2025
    Completion :
    12/30/2027
    ABL1
    |
    Venclexta (venetoclax) • Nailike (olverembatinib)
    ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML (NCT03595917)
    Phase 1
    Marlise Luskin, MD
    Recruiting
    Last update posted :
    12/27/2024
    Initiation :
    07/24/2018
    Primary completion :
    11/01/2025
    Completion :
    11/01/2026
    ABL1 • BCR
    |
    dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)
    Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia (NCT00070499)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    12/27/2024
    Initiation :
    08/15/2004
    Primary completion :
    11/01/2010
    Completion :
    02/22/2025
    ABL1 • BCR
    |
    dasatinib • imatinib
    Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia (NCI-2018-01078) (NCT03263572)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    12/10/2024
    Initiation :
    11/29/2017
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    ABL1 • BCR
    |
    cytarabine • Iclusig (ponatinib) • Blincyto (blinatumomab) • methotrexate • Starasid (cytarabine ocfosfate)
    A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies (KQB198-102) (NCT06645886)
    Phase 1
    Kumquat Biosciences Inc.
    Recruiting
    Last update posted :
    12/05/2024
    Initiation :
    12/01/2024
    Primary completion :
    08/01/2027
    Completion :
    02/01/2028
    ABL1 • BCR
    |
    dasatinib
    Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL (NCT03740334)
    Phase 1
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    10/24/2024
    Initiation :
    01/30/2019
    Primary completion :
    03/04/2023
    Completion :
    04/01/2025
    ABL1 • BCR
    |
    everolimus • Kisqali (ribociclib) • dexamethasone
    ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase (NCT05007873)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    08/27/2024
    Initiation :
    10/21/2021
    Primary completion :
    10/30/2026
    Completion :
    10/30/2026
    ABL1 • BCR
    |
    dasatinib • Inqovi (decitabine/cedazuridine)
    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant (HBO-UBC) (NCT03739502)
    Phase 2
    University of Rochester
    Recruiting
    Last update posted :
    08/19/2024
    Initiation :
    02/28/2019
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A
    |
    FLT3-ITD mutation • NPM1 mutation
    Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PInNACLe) (NCT02001818)
    Phase 2
    Australasian Leukaemia and Lymphoma Group
    Completed
    Last update posted :
    08/06/2024
    Initiation :
    04/11/2014
    Primary completion :
    01/07/2022
    Completion :
    01/07/2022
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib) • ViraferonPeg (peginterferon-α-2b)
    Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older (NCT02494882)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/29/2024
    Initiation :
    06/29/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP
    |
    BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R
    |
    dasatinib • Jakafi (ruxolitinib) • dexamethasone
    Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib (NCT06516029)
    Phase N/A
    Novartis
    Completed
    Last update posted :
    07/23/2024
    Initiation :
    04/21/2023
    Primary completion :
    10/02/2023
    Completion :
    10/02/2023
    ABL1
    |
    Scemblix (asciminib)
    Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. (ASC4TARGET) (NCT06514534)
    Phase 2
    Novartis Pharmaceuticals
    Not yet recruiting
    Last update posted :
    07/23/2024
    Initiation :
    12/02/2024
    Primary completion :
    12/01/2028
    Completion :
    12/01/2028
    ABL1 • BCR
    |
    Iclusig (ponatinib) • Scemblix (asciminib)
    Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia (NCT00254423)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    11/08/2005
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    ABL1 • BCR • IFNA1
    |
    dasatinib
    Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (NCT02356159)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    09/24/2015
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C
    |
    Chr t(9;11)
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • sirolimus • fludarabine IV • Kepivance (palifermin)
    Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia (ASC4KIDS) (NCT04925479)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    12/27/2021
    Primary completion :
    06/30/2026
    Completion :
    11/01/2031
    ABL1 • BCR
    |
    Scemblix (asciminib)